Preferred Label : Anti-Claudin 18.2 Antibody-drug Conjugate JS107;
NCIt synonyms : ADC JS107; Anti-CLDN18.2 ADC JS107; Anti-Claudin 18.2/MMAE Antibody-drug Conjugate JS107; Anti-Claudin 18.2 ADC JS107;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18)
conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE),
with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC JS107
specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization
and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule
polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.2-expressing
tumor cells. In addition, JS107 kills tumor cells via antibody-dependent cellular
cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). CLDN18.2, a tight
junction protein and stomach-specific isoform of claudin-18, is expressed on a variety
of tumor cells. Its expression in healthy tissues is strictly confined to short-lived
differentiated epithelial cells of the gastric mucosa.;
Molecule name : JS-107; JS 107;
NCI Metathesaurus CUI : CL1799102;
Origin ID : C190687;
UMLS CUI : C5783857;
Semantic type(s)
- concept_is_in_subset
- has_target
